Benjamin Bowe1, Yan Xie1, Hong Xian1,2, Tingting Li1,3, Ziyad Al-Aly4,3,5,6. 1. Clinical Epidemiology Center, Research and Education Service and. 2. Department of Biostatistics, College for Public Health and Social Justice, St. Louis University, St. Louis, Missouri; and. 3. Department of Medicine and. 4. Clinical Epidemiology Center, Research and Education Service and zalaly@gmail.com. 5. Division of Nephrology, Department of Medicine, US Department of Veterans Affairs St. Louis Health Care System, St. Louis, Missouri. 6. Institute for Public Health, Washington University School of Medicine, St. Louis, Missouri.
Abstract
BACKGROUND AND OBJECTIVES: Experimental evidence suggests a role for monocytes in the biology of kidney disease progression; however, whether monocyte count is associated with risk of incident CKD, CKD progression, and ESRD has not been examined in large epidemiologic studies. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: We built a longitudinal observational cohort of 1,594,700 United States veterans with at least one eGFR during fiscal year 2004 (date of last eGFR during this period designated time zero) and no prior history of ESRD, dialysis, or kidney transplant. Cohort participants were followed until September 30, 2013 or death. Monocyte count closest to and before time zero was categorized in quartiles: quartile 1, >0.00 to ≤0.40 thousand cells per cubic millimeter (k/cmm); quartile 2, >0.40 to ≤0.55 k/cmm; quartile 3, >0.55 to ≤0.70 k/cmm; and quartile 4, >0.70 k/cmm. Survival models were built to examine the association between monocyte count and risk of incident eGFR<60 ml/min per 1.73 m2, risk of incident CKD, and risk of CKD progression defined as doubling of serum creatinine, eGFR decline ≥30%, or the composite outcome of ESRD, dialysis, or renal transplantation. RESULTS: Over a median follow-up of 9.2 years (interquartile range, 8.3-9.4); in adjusted survival models, there was a graded association between monocyte counts and risk of renal outcomes. Compared with quartile 1, quartile 4 was associated with higher risk of incident eGFR<60 ml/min per 1.73 m2 (hazard ratio, 1.13; 95% confidence interval, 1.12 to 1.14) and risk of incident CKD (hazard ratio, 1.15; 95% confidence interval, 1.13 to 1.16). Quartile 4 was associated with higher risk of doubling of serum creatinine (hazard ratio, 1.22; 95% confidence interval, 1.20 to 1.24), ≥30% eGFR decline (hazard ratio, 1.18; 95% confidence interval, 1.17 to 1.19), and the composite renal end point (hazard ratio, 1.19; 95% confidence interval, 1.16 to 1.22). Cubic spline analyses of the relationship between monocyte count levels and renal outcomes showed a linear relationship, in which risk was higher with higher monocyte count. Results were robust to changes in sensitivity analyses. CONCLUSIONS: Our results show a significant association between higher monocyte count and risks of incident CKD and CKD progression to ESRD.
BACKGROUND AND OBJECTIVES: Experimental evidence suggests a role for monocytes in the biology of kidney disease progression; however, whether monocyte count is associated with risk of incident CKD, CKD progression, and ESRD has not been examined in large epidemiologic studies. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: We built a longitudinal observational cohort of 1,594,700 United States veterans with at least one eGFR during fiscal year 2004 (date of last eGFR during this period designated time zero) and no prior history of ESRD, dialysis, or kidney transplant. Cohort participants were followed until September 30, 2013 or death. Monocyte count closest to and before time zero was categorized in quartiles: quartile 1, >0.00 to ≤0.40 thousand cells per cubic millimeter (k/cmm); quartile 2, >0.40 to ≤0.55 k/cmm; quartile 3, >0.55 to ≤0.70 k/cmm; and quartile 4, >0.70 k/cmm. Survival models were built to examine the association between monocyte count and risk of incident eGFR<60 ml/min per 1.73 m2, risk of incident CKD, and risk of CKD progression defined as doubling of serum creatinine, eGFR decline ≥30%, or the composite outcome of ESRD, dialysis, or renal transplantation. RESULTS: Over a median follow-up of 9.2 years (interquartile range, 8.3-9.4); in adjusted survival models, there was a graded association between monocyte counts and risk of renal outcomes. Compared with quartile 1, quartile 4 was associated with higher risk of incident eGFR<60 ml/min per 1.73 m2 (hazard ratio, 1.13; 95% confidence interval, 1.12 to 1.14) and risk of incident CKD (hazard ratio, 1.15; 95% confidence interval, 1.13 to 1.16). Quartile 4 was associated with higher risk of doubling of serum creatinine (hazard ratio, 1.22; 95% confidence interval, 1.20 to 1.24), ≥30% eGFR decline (hazard ratio, 1.18; 95% confidence interval, 1.17 to 1.19), and the composite renal end point (hazard ratio, 1.19; 95% confidence interval, 1.16 to 1.22). Cubic spline analyses of the relationship between monocyte count levels and renal outcomes showed a linear relationship, in which risk was higher with higher monocyte count. Results were robust to changes in sensitivity analyses. CONCLUSIONS: Our results show a significant association between higher monocyte count and risks of incident CKD and CKD progression to ESRD.
Authors: W Gao; P S Topham; J A King; S T Smiley; V Csizmadia; B Lu; C J Gerard; W W Hancock Journal: J Clin Invest Date: 2000-01 Impact factor: 14.808
Authors: Khurram Nasir; Eliseo Guallar; Ana Navas-Acien; Michael H Criqui; João A C Lima Journal: Arterioscler Thromb Vasc Biol Date: 2005-06-23 Impact factor: 8.311
Authors: Kathyrn D Rodgers; Velidi Rao; Daniel T Meehan; Nicole Fager; Philip Gotwals; Sarah T Ryan; Victor Koteliansky; Ryoichi Nemori; Dominic Cosgrove Journal: Kidney Int Date: 2003-04 Impact factor: 10.612
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Benjamin Bowe; Yan Xie; Hong Xian; Sumitra Balasubramanian; Mohamed A Zayed; Ziyad Al-Aly Journal: Clin J Am Soc Nephrol Date: 2016-08-11 Impact factor: 8.237
Authors: Scott M Lundberg; Gabriel Erion; Hugh Chen; Alex DeGrave; Jordan M Prutkin; Bala Nair; Ronit Katz; Jonathan Himmelfarb; Nisha Bansal; Su-In Lee Journal: Nat Mach Intell Date: 2020-01-17
Authors: Koenraad R P Veys; Mohamed A Elmonem; Maria Van Dyck; Mirian C Janssen; Elisabeth A M Cornelissen; Katharina Hohenfellner; Giusi Prencipe; Lambertus P van den Heuvel; Elena Levtchenko Journal: J Am Soc Nephrol Date: 2020-04-09 Impact factor: 10.121
Authors: L Čurnová; K Mezerová; V Švachová; M Fialová; M Novotný; E Čečrdlová; O Viklický; I Stříž Journal: Physiol Res Date: 2020-09-09 Impact factor: 1.881
Authors: Benjamin Bowe; Miao Cai; Yan Xie; Andrew K Gibson; Geetha Maddukuri; Ziyad Al-Aly Journal: Clin J Am Soc Nephrol Date: 2020-11-16 Impact factor: 8.237